Journal of the National Cancer Institute Advance Access originally published online on March 25, 2008
JNCI Journal of the National Cancer Institute 2008 100(7):449-450; doi:10.1093/jnci/djn061
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press.
EDITORIALS |
Early Adoption and Disturbing Disparities in Sentinel Node Biopsy in Breast Cancer
Affiliation of author: Roswell Park Cancer Institute, Buffalo, NY
Correspondence to: Stephen B. Edge, MD, Roswell Park Cancer Institute, Buffalo, NY (e-mail: stephen.edge@roswellpark.org).
| The first 10% of the full text of this article appears below. |
Axillary lymph node surgery remains an integral component of breast cancer treatment. Node status provides key prognostic information that is used to direct adjuvant systemic therapy (1). Removal of the nodes may also improve local control, although the preponderance of data shows no survival advantage with node dissection itself (2).
Until recently, surgery required full axillary lymph node dissection (ALND). However, recovery from ALND is painful, and the procedure carries the risk of permanent lymphedema. In the early 1990s, it was hypothesized that colloidal material injected into the breast would drain to the same first node(s) as the cancer (3,4). The commonly used agents are radiolabeled sulfur colloid alone or in combination with a blue dye (isosulfan blue or methylene blue), which are detected by a
Related Articles in JNCI
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2008 100: 462-474.
J Natl Cancer Inst 2008 100: 447.